Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter, Single-Arm, Open-Label Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
2010-023856-97Phase 3Completed
- Sponsor
- Biogen
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Incidence of anti-DAC HYP binding antibodies. Started Jul 2011; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2010-023856-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023856-97.